XCUR: Exicure Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for XCUR
Across the 6 sessions after earlier XCUR headlines, the stock closed higher 4 times and lower 1 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | XCUR | SPY |
|---|---|---|---|
| Apr 23, 2026 | Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) | +0.1% | -0.4% |
| Mar 26, 2026 | Exicure, Inc. Reports Full Year 2025 Financial Results | +0.0% | -1.8% |
| Feb 5, 2026 | Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant | +4.4% | -1.2% |
| Jan 21, 2026 | Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings | +2.3% | +1.2% |
| Dec 9, 2025 | Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting | +36.8% | -0.1% |
| Nov 10, 2025 | Exicure, Inc. Reports Third Quarter 2025 Financial Results | -2.3% | +1.6% |
Quantisnow market dataNASDAQ
XCUR
Exicure Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for XCUR
Full XCUR profile on Quantisnow Follow XCUR and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time